Otsuka Holdings

Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine . Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.In July 2017, they bought DaiyaIn July 2018, Otsuka agreed to acquire Visterra for $430 million cash.

To prevent and alleviate human suffering in the face of emergencies by mobilizing the power of volunteers and the generosity of donors."

Improve every day